Lantheus reports Q3 2026 results, gains two approvals amid pending Curium merger
FDA clearances for TAUKLARIFY and BRAVNETSA arrive as Lantheus moves toward its announced $8 billion acquisition by Curium.
Lantheus Holdings reported third quarter 2026 results on November 5, 2026, alongside a string of regulatory and pipeline updates tied to an announced merger with Curium.
The FDA approved TAUKLARIFY (florquinitau F-18 injection), an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer's disease.1 The company said it intends to continue supporting Alzheimer's disease therapeutic programs through its Pharma Solutions business while assessing the appropriate path toward broader commercial availability.1
Separately, the FDA granted final approval for BRAVNETSA (lutetium Lu 177 dotatate), the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors; the Company is preparing for a thoughtful commercial launch to support reliable supply and broad patient access.1
On the pipeline side, Lantheus dosed the first patient in the SPARROW study, a Phase 2/3 registrational trial evaluating LNTH-2401, the Company's investigational GRPR-targeted PET imaging agent for prostate cancer; the Phase 3 portion is expected to enroll approximately 400 participants and evaluate diagnostic performance, safety and tolerability.1
The company also noted it received CMS Transitional Pass-Through payment status and a permanent HCPCS code, each effective October 1, 2026, for PYLARIFY TruVu (piflufolastat F18), supporting the Company's previously announced phased geographic commercial launch.1
On financing, at September 30, 2026, the Company's cash and cash equivalents were $683.6 million, compared to $359.1 million at December 31, 2025,1 and it currently has access to up to $750.0 million from a revolving line of credit.1
Given the pending Curium transaction, Lantheus said it is suspending its previously issued full year 2026 financial guidance and will not be hosting a conference call in connection with its third quarter 2026 results.1 Under the merger agreement announced August 3, 2026, Curium US Holdings LLC will acquire all outstanding Lantheus shares for $102.50 per share in cash plus contingent value rights worth up to $12.00 per share tied to commercial milestones through 2030, for total per share consideration of up to $114.50 and a transaction value of up to approximately $8.0 billion.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.